February 27, 2020 / 10:13 PM / a month ago

IN BRIEF: Fed Circuit denies Biogen bid to halt sales of Tecfidera competitor

A federal appeals court on Thursday said it would not block Banner Life Sciences LLC from selling a version of the Biogen Inc multiple-sclerosis drug Tecfidera while the court hears a patent dispute between the companies.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied a request by Biogen’s lawyers at Finnegan Henderson Farabow Garrett & Dunner for an injunction pending the outcome of their appeal of a recent ruling that cleared the way for Banner’s product launch.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2wUSOPV

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below